VR Logo

Avadel Pharmaceuticals plc (AVDL) download report


Healthcare | Drugs & Pharma

Avadel Pharmaceuticals plc (AVDL) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.

IPO Date: 07-Jun-1996

CEO & Director: Mr. Gregory J. Divis Jr.

Sr. VP & CFO: Mr. Thomas S. McHugh

Listing: NASDAQ: AVDL

Country: Ireland

Headquarters: Dublin,

Website: https://www.avadel.com

Key Facts

Market cap: $347.14 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-90.31 Mln

Cash: $123.48 Mln

Total Debt: $145.13 Mln

Insider's Holding: 7.14%

Liquidity: Low

52 Week range: $1.05 - 11.59

Shares outstanding: 59,038,200

10 Years Aggregate:

  • CFO: $-181.66 Mln
  • EBITDA: $-110.07 Mln
  • Net Profit: $-262.24 Mln

Stock Performance

Time Period Avadel Pharmaceuticals (AVDL) S&P BSE Healthcare* S&P Small-Cap 600*
YTD-27.23-11.25-11.58
1 month128.795.368.86
3 months25.371.49-2.19
1 Year-24.71-11.80-6.23
3 Years38.9922.769.73
5 Years-8.6810.867.72
10 Years1.7412.2710.81
As on 05-Aug-2022 *As on 08-Aug-2022
Year Avadel Pharmaceuticals (AVDL) S&P Small-Cap 600 S&P BSE Healthcare
202120.9625.2720.87
2020-11.529.5761.45
2019192.6420.86-3.55
2018-68.34-9.70-5.89
2017-21.0811.730.49
2016-14.9124.74-12.88
2015-28.72-3.3615.06